Colosia A, Njue A, Bajwa Z, Dragon E, Robinson RL, Sheffield KM, Thakkar S, Richeimer SH. The burden of metastatic cancer-induced bone pain: a narrative review. J Pain Res. 2022 Oct 25;2022(15):3399-412. doi: 10.2147/JPR.S371337
Gonzalez JM, Johnson FR, Runken MC, Poulos CM. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013 Nov;53(10):1635-50.
Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226
Pladevall M, Zografos L, Tatt I, Napalkov P, Andrews E, Perez-Gutthann S. Feasibility evaluation for a rituximab utilization study to be conducted in infusion centers. Poster presented at the 29th International Conference on Pharmacoepidemiology; August 2013.
Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375
Copley-Merriman K, Olanrewaju B, Hogue S. The temporal relationship between NSAIDS and risk of gastrointestinal, cardiovascular, and renal events: a systematic review. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2, 2013. [abstract] Value Health. 2013 May; 16(3):A110.
Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Course of pain and outcomes of depression. Results from a three - month, prospective, observational study from Asia. Poster presented at the Eleventh Workshop on Costs and Assessment in Psychiatry; March 2013. Venice, Italy. [abstract] J Ment Health Policy Econ. 2013 Mar; 16(Suppl 1):S27-8.
Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Does the presence of co-morbid conditions explain the impact of pain in depression outcomes? Poster presented at the Eleventh Workshop on Costs and Assessment in Psychiatry; March 2013. Venice, Italy. [abstract] J Ment Health Policy Econ. 2013 Mar; 16(1):S27.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Williams VS, Smith MY, Fehnel SE. The validity and utility of bpi interference measures addressing the impact of pain. Poster presented at the Annual International Society for Quality of Life Research (ISOQOL) Conference; November 2003.
Allen RM, Granger AL, Dykstra LA. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov 1;307(2):785-92.
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.
Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. Safety profile of smell and taste disorders in patients treated with cox-2 specific inhibitors and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.
Rothman KJ, Wepsic JG. Side of facial pain in trigeminal neuralgia. J Neurosurg. 1974 Jan 1;40(4):514-6.